<?xml version="1.0" encoding="UTF-8"?>
<p id="Par20">Furthermore, based on enrichment analysis of key co-targets, the PPAR signalling pathway
 <sup>
  <xref ref-type="bibr" rid="CR45">45</xref>
 </sup> was most correlated with anti-hepatic fibrosis in SCST (
 <italic>P</italic> = 0.00364). Related studies have shown that the PPAR pathway is involved in adipogenesis, lipid metabolism, inflammation and the maintenance of metabolic homeostasis. The effects of PPARγ agonism on the liver remain under debate, with some studies showing that it promotes hepatic steatosis through upregulation of the genes involved in lipid uptake and storage and other studies showing that it prevents hepatic steatosis and fibrosis
 <sup>
  <xref ref-type="bibr" rid="CR46">46</xref>
 </sup>. The "compound-target-pathway" network model is shown in Fig. 
 <xref rid="Fig2" ref-type="fig">2</xref>.
</p>
